非洲脑膜炎带肺炎球菌性脑膜炎暴发控制策略建模
该研究以布基纳法索、乍得和加纳近期肺炎球菌性脑膜炎暴发为案例,用数学模型评估反应性接种肺炎球菌结合疫苗(PCV)的潜在影响与效率,并与现有婴儿常规免疫比较。结果显示反应性接种最多可避免10-20%的暴发病例,需接种人数在大型和/或 prolonged 暴发中低于10,000。
要点
- 反应性接种PCV在既往暴发中最多可避免10-20%的暴发病例。
- 大型和/或 prolonged 暴发的需接种人数估计低于10,000。
- 婴儿常规免疫PCV的需接种人数:布基纳法索3,100-5,600,加纳1,500-2,600。
核心结论
- 在非洲脑膜炎带的肺炎球菌性脑膜炎暴发中,实施反应性接种PCV最多可避免10-20%的暴发病例,其中加纳Brong Ahafo(2015-2016)和乍得Goundi(2009)的潜在影响最大。
- 需接种人数和反应性接种的价值差异很大,大型(每10万人口累计模拟病例80例以上)和/或 prolonged(每10万人口每周10例疑似病例的响应阈值持续四周或以上)暴发的需接种人数估计低于10,000。
- 作者认为,各国应在每次暴发事件中考虑反应性接种,同时维持婴儿常规免疫作为减少肺炎球菌疾病负担和暴发风险的主要干预措施。
研究设计与样本
- 研究使用布基纳法索、乍得和加纳近期肺炎球菌性脑膜炎暴发作为案例研究,通过数学模型评估反应性接种PCV的潜在影响。
- 研究计算了每次暴发和所有暴发中避免一例病例所需的接种人数(NNV),并与现有婴儿常规接种PCV的NNV进行比较。
- 研究扩展了先前对反应性接种的分析,考虑了疫苗接种者五年内的长期保护,并纳入了间接效应的替代指标。
主要发现
- 在既往肺炎球菌性脑膜炎暴发中实施反应性接种最多可避免10-20%的暴发病例,最大潜在影响在加纳Brong Ahafo(2015-2016)和乍得Goundi(2009)。
- 需接种人数和反应性接种的价值差异很大;大型(每10万人口累计模拟病例80例以上)和/或 prolonged(每10万人口每周10例疑似病例的响应阈值持续四周或以上)暴发的NNV估计低于10,000。
- 婴儿常规接种PCV的估计NNV在布基纳法索为3,100-5,600,在加纳为1,500-2,600。
关键数值与推荐
- 大型暴发定义为每10万人口累计模拟病例80例以上。
- Prolonged 暴发定义为超过每10万人口每周10例疑似病例的响应阈值持续四周或以上。
- 大型和/或 prolonged 暴发的NNV估计低于10,000。
- 婴儿常规接种PCV的NNV:布基纳法索3,100-5,600,加纳1,500-2,600。
临床怎么用
- 作者认为,各国应在每次暴发事件中考虑反应性接种。
- 作者认为,应维持婴儿常规免疫作为减少肺炎球菌疾病负担和暴发风险的主要干预措施。
- 该分析为肺炎球菌性脑膜炎暴发应对指南的设计提供了证据。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Pneumococcal meningitis outbreaks occur sporadically in the African meningitis belt. Outbreak control guidelines and interventions are well established for meningococcal but not pneumococcal meningitis. Mathematical modelling is a useful tool for assessing the potential impact of different pneumococcal control strategies. This work aimed to estimate the impact of reactive vaccination with pneumococcal conjugate vaccine (PCV) had it been implemented in past African meningitis belt outbreaks and assess their efficiency relative to existing routine infant immunisation with PCV. METHODS & RESULTS: Using recent pneumococcal meningitis outbreaks in Burkina Faso, Chad, and Ghana as case studies, we investigated the potential impact of reactive vaccination. We calculated the number needed to vaccinate to avert one case (NNV) in each outbreak setting and over all outbreaks and compared this to the NNV for existing routine infant vaccination. We extended previous analyses of reactive vaccination by considering longer-term protection in vaccinees over five years, incorporating a proxy for indirect effects. We found that implementing reactive vaccination in previous pneumococcal meningitis outbreaks could have averted up to 10-20 % of outbreak cases, with the biggest potential impact in Brong Ahafo, Ghana (2015-2016) and Goundi, Chad (2009). The NNV, and hence the value of reactive vaccination, varied greatly. 'Large' (80 + cumulative modelled cases per 100,000 population) and/or 'prolonged' (exceeding a response threshold of 10 suspected cases per 100,000 per week for four weeks or more) outbreaks had NNV estimates under 10,000. For routine infant vaccination with PCV, the estimated NNV ranged from 3,100-5,600 in Burkina Faso and 1,500-2,600 in Ghana. IMPLICATIONS: This analysis provides evidence to inform the design of pneumococcal meningitis outbreak response guidelines. Countries should consider reactive vaccination in each outbreak event, together with maintaining routine infant vaccination as the primary intervention to reduce pneumococcal disease burden and outbreak risk.
引用
- Hadley L, Soeters HM, Cooper LV, et al. Modelling control strategies for pneumococcal meningitis outbreaks in the African meningitis belt. Vaccine. 2024. PMID: 38797628. doi:10.1016/j.vaccine.2024.05.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。